We have located links that may give you full text access.
PHASES and ELAPSS Scores Are Associated with Aneurysm Growth: A Study of 431 Unruptured Intracranial Aneurysms.
World Neurosurgery 2018 June
BACKGROUND: Understanding risk factors for intracranial aneurysm growth is important for patient management. We performed a retrospective study examining risk factors for the growth of unruptured intracranial aneurysms followed at our institution, evaluating both traditional risk factors and the PHASES (Population, Hypertension, Age, Size, Earlier Subarachnoid Hemorrhage, Site) score.
METHODS: We retrospectively reviewed a consecutive series of unruptured intracranial aneurysms followed at our institution for a minimum of 6 months over a 15-year period. The primary outcome of this study was aneurysm growth, defined as a ≥1-mm increase in maximum diameter. Risk factors studied included PHASES score, ELAPSS (Earlier Subarachnoid Hemorrhage, Location of Aneurysm, Age, Population, Size, and Shape) score, demographics, multiple aneurysms, previous subarachnoid hemorrhage, family history of aneurysm or subarachnoid hemorrhage, smoking, hypertension, and aneurysm shape, size, and location. The χ2 test was used for comparison of categorical variables, and the Student t test was used for continuous variables.
RESULTS: The study cohort comprised 352 patients with a total of 431 unruptured intracranial aneurysms. The mean duration of follow-up was 4.8 years, and there was a total of 2100 aneurysm-years of follow-up. Forty aneurysms (9.3%) grew, for an annualized growth rate of 2.0% of aneurysms/year. Current smoking status was the sole modifiable risk factor associated with growth (growth rate of 5.1%/year compared with 1.5%/year for never smokers; P = 0.0004). Increasing size (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.11-1.33; P < 0.0001), ELAPSS score (OR, 1.10; 95% CI, 1.09-1.11; P < 0.0001), and PHASES score (OR, 1.24; 95% CI, 1.20-1.28; P < 0.0001) were associated with growth as well. Age, location, previous subarachnoid hemorrhage, and hypertension were not independently associated with aneurysm growth.
CONCLUSIONS: Our retrospective study suggests that aneurysm size, smoking status, PHASES score, and ELAPSS score are associated with aneurysm growth.
METHODS: We retrospectively reviewed a consecutive series of unruptured intracranial aneurysms followed at our institution for a minimum of 6 months over a 15-year period. The primary outcome of this study was aneurysm growth, defined as a ≥1-mm increase in maximum diameter. Risk factors studied included PHASES score, ELAPSS (Earlier Subarachnoid Hemorrhage, Location of Aneurysm, Age, Population, Size, and Shape) score, demographics, multiple aneurysms, previous subarachnoid hemorrhage, family history of aneurysm or subarachnoid hemorrhage, smoking, hypertension, and aneurysm shape, size, and location. The χ2 test was used for comparison of categorical variables, and the Student t test was used for continuous variables.
RESULTS: The study cohort comprised 352 patients with a total of 431 unruptured intracranial aneurysms. The mean duration of follow-up was 4.8 years, and there was a total of 2100 aneurysm-years of follow-up. Forty aneurysms (9.3%) grew, for an annualized growth rate of 2.0% of aneurysms/year. Current smoking status was the sole modifiable risk factor associated with growth (growth rate of 5.1%/year compared with 1.5%/year for never smokers; P = 0.0004). Increasing size (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.11-1.33; P < 0.0001), ELAPSS score (OR, 1.10; 95% CI, 1.09-1.11; P < 0.0001), and PHASES score (OR, 1.24; 95% CI, 1.20-1.28; P < 0.0001) were associated with growth as well. Age, location, previous subarachnoid hemorrhage, and hypertension were not independently associated with aneurysm growth.
CONCLUSIONS: Our retrospective study suggests that aneurysm size, smoking status, PHASES score, and ELAPSS score are associated with aneurysm growth.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app